QTORIN™ rapamycin 3.9%is a novel targeted topical therapy being studied for Gorlin syndrome. Palvella is enrolling a phase 2b clinical study (CODY) for people with Gorlin syndrome.
A lifelong risk of malignant skin cancer
Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, is a serious rare life-long genetic disease caused by a mutation in the PTCH1 gene leading to abherrant hedgehog signaling. Recurrent basal cell carcinomas (BCCs) are a hallmark of this disease. Individuals with Gorlin syndrome can develop hundreds or even thousands of BCCs, oftentimes beginning in childhood. BCCs are a malignant skin cancer requiring repeated and potentially disfiguring surgical removal for patients with Gorlin syndrome. Gorlin syndrome affects an estimated 11,000 people in the United States.
There are no FDA approved therapies for Gorlin syndrome.
Palvella initiated internal research efforts on the potential for QTORIN™ rapamycin 3.9% in Gorlin syndrome in 2017. QTORIN™ rapamycin 3.9% is designed to inhibit the mTOR pathway, a major driver of BCC tumorigenesis¹,2. This approach aims to avoid some of the limitations of the direct hedgehog inhibitors, such as resistance and recurrence.
Hua, H., Kong, Q., Zhang, H. et al. Targeting mTOR for cancer therapy. J Hematol Oncol 12, 71 (2019) doi:10.1186/s13045-019-0754-1
Kim, A., Back, J. et al. SOX9 Transcriptionally Regulates mTOR-Induced Proliferation of Basal Cell Carcinomas. J Invest Dermatol. 2018 August; 138(8): 1716–1725.
The Gorlin syndrome clinical study is now enrolling
Palvella is enrolling a phase 2b clinical study for the prevention of BCCs in patients with Gorlin syndrome. Please use the link below to learn more about this study.
Cannot have participated in another Gorlin clinical study in past 3 months
Resources for Gorlin
Gorlin Syndrome Alliance
Founded in 2000, the Gorlin Syndrome Alliance is the primary patient advocacy group for Gorlin Syndome in the U.S. Their mission is to thoughtfully support, comprehensively educate and aggressively seek treatments and a cure for Gorlin Syndrome, its manifestations, and BCCs.
National Organization for Rare Disorders
NORD is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 280 patient organizations members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.
We’re uncovering more therapies every day. Don’t miss out.